JP7676141B2 - ジヒドロオキサジアジノン - Google Patents

ジヒドロオキサジアジノン Download PDF

Info

Publication number
JP7676141B2
JP7676141B2 JP2020505898A JP2020505898A JP7676141B2 JP 7676141 B2 JP7676141 B2 JP 7676141B2 JP 2020505898 A JP2020505898 A JP 2020505898A JP 2020505898 A JP2020505898 A JP 2020505898A JP 7676141 B2 JP7676141 B2 JP 7676141B2
Authority
JP
Japan
Prior art keywords
groups
dihydro
oxadiazin
trifluoromethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529439A5 (enExample
JP2020529439A (ja
Inventor
マヌエル・エラーマン
シュテファン・ニコラウス・グラドル
シャルロッテ・クリスティーネ・コーピッツ
マルティン・ランゲ
アドリアン・テルシュテーゲン
フィリップ・リーナウ
クリスタ・ヘーゲレ－ハルトゥング
デトレフ・ズュルツレ
ティモシー・エー・ルイス
ハイディ・グルーリック
シャオユン・ウ
マシュー・メイヤーソン
アレックス・バーギン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2020529439A publication Critical patent/JP2020529439A/ja
Publication of JP2020529439A5 publication Critical patent/JP2020529439A5/ja
Priority to JP2023097166A priority Critical patent/JP2023115065A/ja
Application granted granted Critical
Publication of JP7676141B2 publication Critical patent/JP7676141B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020505898A 2017-08-04 2018-08-02 ジヒドロオキサジアジノン Active JP7676141B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023097166A JP2023115065A (ja) 2017-08-04 2023-06-13 ジヒドロオキサジアジノン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541627P 2017-08-04 2017-08-04
US62/541,627 2017-08-04
PCT/EP2018/071039 WO2019025562A1 (en) 2017-08-04 2018-08-02 DIHYDROOXADIAZINONES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097166A Division JP2023115065A (ja) 2017-08-04 2023-06-13 ジヒドロオキサジアジノン

Publications (3)

Publication Number Publication Date
JP2020529439A JP2020529439A (ja) 2020-10-08
JP2020529439A5 JP2020529439A5 (enExample) 2021-09-09
JP7676141B2 true JP7676141B2 (ja) 2025-05-14

Family

ID=63207725

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505898A Active JP7676141B2 (ja) 2017-08-04 2018-08-02 ジヒドロオキサジアジノン
JP2023097166A Pending JP2023115065A (ja) 2017-08-04 2023-06-13 ジヒドロオキサジアジノン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023097166A Pending JP2023115065A (ja) 2017-08-04 2023-06-13 ジヒドロオキサジアジノン

Country Status (26)

Country Link
US (3) US11427553B2 (enExample)
EP (1) EP3661517B1 (enExample)
JP (2) JP7676141B2 (enExample)
KR (1) KR20200036914A (enExample)
CN (1) CN111212647B (enExample)
AR (1) AR112402A1 (enExample)
AU (1) AU2018309356B2 (enExample)
BR (1) BR112020002351A2 (enExample)
CA (1) CA3071800A1 (enExample)
CL (1) CL2020000303A1 (enExample)
CO (1) CO2020001242A2 (enExample)
CR (1) CR20200057A (enExample)
CU (1) CU24608B1 (enExample)
EA (1) EA202090448A1 (enExample)
EC (1) ECSP20008441A (enExample)
IL (1) IL272098B2 (enExample)
JO (1) JOP20200024A1 (enExample)
MA (1) MA49750A (enExample)
MX (1) MX2020001404A (enExample)
PE (1) PE20200936A1 (enExample)
PH (1) PH12020500134A1 (enExample)
SG (1) SG11201913775UA (enExample)
TW (1) TWI791581B (enExample)
UA (1) UA125731C2 (enExample)
UY (1) UY37832A (enExample)
WO (1) WO2019025562A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023115065A (ja) * 2017-08-04 2023-08-18 バイエル アクチェンゲゼルシャフト ジヒドロオキサジアジノン

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
TW202031677A (zh) 2018-11-01 2020-09-01 美商博得學院股份有限公司 Ｐｄｅ３調節劑反應性癌症之鑑定
WO2020157188A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Dihydrooxadiazinones for the treatment of hyperproliferative diseases
AU2020215088A1 (en) 2019-02-01 2021-07-22 Bayer Aktiengesellschaft 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases
CN117279644A (zh) 2021-03-03 2023-12-22 拜耳股份有限公司 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮
EP4289828A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one
EP4289829A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one
CN120187704A (zh) * 2022-11-24 2025-06-20 盛睿泽华医药科技（苏州）有限公司 吡啶酮化合物及其制备方法和用途
CN117903077B (zh) * 2023-01-13 2024-09-03 上海超阳药业有限公司 二氢噁二嗪酮化合物及其应用
CN118420559B (zh) * 2023-04-27 2025-02-14 上海超阳药业有限公司 氘代噁二嗪酮化合物及其用途
CN118047833B (zh) * 2024-01-31 2025-03-14 海南大学 含二茂铁的取代氨基乙酰胺类化合物及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097671A (en) * 1975-08-28 1978-06-27 General Electric Company Dihydrooxadiazinones and method for making
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4258094A (en) * 1979-04-26 1981-03-24 Brunswick Corporation Melt bonded fabrics and a method for their production
US4334030A (en) 1979-11-23 1982-06-08 General Electric Company Thermoplastic foamable blends
DE3172252D1 (en) 1980-11-14 1985-10-17 Ici Plc Heterocyclic compounds
DE3263497D1 (en) 1981-03-04 1985-06-20 Ciba Geigy Ag Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use
ZA827641B (en) 1981-11-12 1983-09-28 Ici Plc Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity
US4495185A (en) 1981-11-12 1985-01-22 Imperial Chemical Industries, Plc 1,2,4-Triazin-3(2H) ones
US4581356A (en) 1983-03-22 1986-04-08 Fujisawa Pharmaceutical Co., Ltd. Triazine derivatives, and pharmaceutical compositions comprising the same
GB8310435D0 (en) 1983-04-18 1983-05-25 Fujisawa Pharmaceutical Co Triazine derivatives
JPS59196874A (ja) 1983-04-22 1984-11-08 Fujisawa Pharmaceut Co Ltd トリアジン誘導体
JPS6153270A (ja) 1984-08-17 1986-03-17 チバ・ガイギー・アクチエンゲゼルシヤフト 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
GB8426804D0 (en) 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
DE3677316D1 (de) 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
EP0303418A3 (en) 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
ATE180475T1 (de) 1990-09-21 1999-06-15 Rohm & Haas Dihydropyridazinone und pyridazinone als fungizide
JPH0676325B2 (ja) * 1992-05-08 1994-09-28 三井東圧化学株式会社 オキサジアジン誘導体を有効成分として含有する抗血栓剤
JPH07508987A (ja) 1992-07-01 1995-10-05 オーソ・フアーマシユーチカル・コーポレーシヨン １−アリールスルホニル，アリールカルボニルおよび１−アリールホスホニル−３−フェニル−１，４，５，６−テトラヒドロピリダジン
JPH07291968A (ja) 1994-04-26 1995-11-07 Mitsubishi Chem Corp トリアジノン誘導体またはその塩類
DE19929787A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung
EP1368035A1 (en) * 2001-02-12 2003-12-10 MERCK PATENT GmbH Use of type 4 phosphodiesterase inhibitors in myocardial diseases
WO2008108602A1 (en) 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5794297B2 (ja) 2010-05-07 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９アゴニストとしてのピリダジノン
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2014164704A2 (en) 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
WO2017027854A1 (en) * 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a or slfn12
US10729680B2 (en) 2016-01-14 2020-08-04 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
TW201733591A (zh) 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
KR101831772B1 (ko) * 2016-03-24 2018-03-06 아이디에스(주) 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
TW202031677A (zh) 2018-11-01 2020-09-01 美商博得學院股份有限公司 Ｐｄｅ３調節劑反應性癌症之鑑定
AU2020215088A1 (en) 2019-02-01 2021-07-22 Bayer Aktiengesellschaft 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023115065A (ja) * 2017-08-04 2023-08-18 バイエル アクチェンゲゼルシャフト ジヒドロオキサジアジノン

Also Published As

Publication number Publication date
CU20200008A7 (es) 2020-11-30
KR20200036914A (ko) 2020-04-07
WO2019025562A1 (en) 2019-02-07
US11773070B2 (en) 2023-10-03
PE20200936A1 (es) 2020-09-17
IL272098A (en) 2020-03-31
CL2020000303A1 (es) 2020-11-13
CR20200057A (es) 2020-06-16
EP3661517B1 (en) 2023-09-13
CN111212647B (zh) 2024-05-14
CO2020001242A2 (es) 2020-02-18
US12258323B2 (en) 2025-03-25
UY37832A (es) 2019-02-28
US11427553B2 (en) 2022-08-30
AR112402A1 (es) 2019-10-23
PH12020500134A1 (en) 2021-01-25
CN111212647A (zh) 2020-05-29
AU2018309356A1 (en) 2020-01-30
CA3071800A1 (en) 2019-02-07
ECSP20008441A (es) 2020-05-29
JP2023115065A (ja) 2023-08-18
BR112020002351A2 (pt) 2020-09-08
MX2020001404A (es) 2020-03-12
JOP20200024A1 (ar) 2020-02-02
MA49750A (fr) 2020-06-10
IL272098B1 (en) 2023-03-01
TWI791581B (zh) 2023-02-11
TW201917126A (zh) 2019-05-01
EP3661517A1 (en) 2020-06-10
US20220396554A1 (en) 2022-12-15
AU2018309356B2 (en) 2022-12-15
JP2020529439A (ja) 2020-10-08
CU24608B1 (es) 2022-06-06
SG11201913775UA (en) 2020-01-30
EA202090448A1 (ru) 2020-05-21
UA125731C2 (uk) 2022-05-25
IL272098B2 (en) 2023-07-01
US20200369633A1 (en) 2020-11-26
US20230017200A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US12258323B2 (en) Dihydrooxadiazinones
JP7747799B2 (ja) ４，５－縮環１，２，４－トリアゾロン
EP3402795B1 (en) 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
CA3137472A1 (en) Acyl sulfonamides for treating cancer
EP4229045A1 (en) Substituted acyl sulfonamides for treating cancer
US20240182452A1 (en) 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JP7582953B2 (ja) 過剰増殖性疾患を治療するための１，２，４－トリアジン－３（２ｈ）－オン化合物
WO2020157201A1 (en) Oxadiazinone compounds for the treatment of hyperproliferative diseases
WO2020157189A1 (en) 1,2,4-triazin-6(1h)-one compounds for the treatment of hyperproliferative diseases
WO2020157199A1 (en) Annulated dihydropyridazinone compounds as anti-cancer compounds
EA041614B1 (ru) Дигидрооксадиазиноны
HK40025099B (en) Dihydrooxadiazinones
WO2020157236A1 (en) Pyridyl substituted dihydrooxadiazinones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230622

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250430

R150 Certificate of patent or registration of utility model

Ref document number: 7676141

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150